Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nurix TherapeuticsNRIX -0.08%59 Cash Ratio is 6.16 as of May. 2026, which is 19% above its 10-year median of 5.19. GuruFocus rates NRIX with a GF Score™ of 59/100 and a GF Value™ of $7.58 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,382 Biotechnology companies, Nurix Therapeutics ranks better than 69.18% on this metric.
Nurix Therapeutics has a Cash Ratio of 6.16. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Nurix Therapeutics's Cash Ratio or its related term are showing as below:
NRIX'
s Cash Ratio Range Over the Past 10 Years
Min: 1.19 Med: 5.19 Max: 8.64
Current: 6.16
During the past 8 years, Nurix Therapeutics's highest Cash Ratio was 8.64. The lowest was 1.19. And the median was 5.19.
NRIX's Cash Ratio is ranked better than 69.18% of 1382
companies
in the Biotechnology industry
Industry Median: 2.93
vs NRIX: 6.16
Nurix Therapeutics (NAS:NRIX) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Nurix Therapeutics Cash Ratio Related Terms
Nurix Therapeutics Cash Ratio Historical Data
* Premium members only.
The historical data trend for Nurix Therapeutics's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Nurix Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nurix Therapeutics Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nurix Therapeutics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Nurix Therapeutics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nurix Therapeutics (NRIX) has a Cash Ratio of 6.16 as of May. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Nurix Therapeutics and its competitors. This is 19% above median its historical median of 5.19. Over the past decade, Nurix Therapeutics' Cash Ratio has ranged from 1.19 to 8.64. According to the industry distribution chart, Nurix Therapeutics ranks #426 out of 1382 companies in the Biotechnology industry, placing it in the top 30.8%.
Is Nurix Therapeutics' Cash Ratio too high?
Nurix Therapeutics' current Cash Ratio of 6.16 is 19% above median its 10-year median of 5.19. Over the past 10 years, this metric has ranged from a low of 1.19 to a high of 8.64. The Biotechnology industry median Cash Ratio is 2.93. Nurix Therapeutics' value of 6.16 is 110.2% above this industry median. Based on the distribution chart, Nurix Therapeutics ranks #426 out of 1382 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Nurix Therapeutics has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nurix Therapeutics' Cash Ratio compare to ATAI and SLS?
According to the Biotechnology industry distribution chart, Nurix Therapeutics ranks #426 out of 1382 companies for Cash Ratio. This puts Nurix Therapeutics in the upper half of its industry. The industry median Cash Ratio is 2.93. Nurix Therapeutics' value of 6.16 is 110.2% above this benchmark. Historically, Nurix Therapeutics' own Cash Ratio has ranged from 1.19 to 8.64 over the past decade. While the company's 10-year median is 5.19 vs. the industry median of 2.93, Nurix Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,382 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nurix Therapeutics's current Cash Ratio of 6.16 is 110.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Nurix Therapeutics and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nurix Therapeutics's current Cash Ratio is 6.16, which is 19% above median its own 10-year median of 5.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nurix Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nurix Therapeutics (NRIX) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.58, compared to a current price of $26.13 — trading 244.7% above its estimated fair value. The current Cash Ratio is 6.16, which is 19% above median its 10-year median of 5.19 and 110.2% above the Biotechnology industry median of 2.93. Nurix Therapeutics' overall GF Score™ is 59/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Nurix Therapeutics (NRIX), the current Cash Ratio is 6.16 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nurix Therapeutics (NRIX) Overvalued in 2026?
Based on GuruFocus' analysis, Nurix Therapeutics stock appears to be overvalued.
The current stock price of $26.13 is trading 244.7% above its estimated GF Value™ of $7.58.
GuruFocus considers Nurix Therapeutics to be Significantly Overvalued.
Key valuation signals for NRIX:
Cash Ratio: 6.16 (19% above median its 10-year median of 5.19)
GF Value™: $7.58 vs. price of $26.13 (244.7% above fair value)
Industry Position: 110.2% above the Biotechnology median (#426 of 1382)
No single metric tells the full story. See the NRIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
59GF Score
Get the complete analysis for NRIX
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NRIX has been successfully added to your 
